MedTrace Logo

A Real-World Study of Bispecific Antibodies in Multiple Myeloma

NCT06359067 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-04-11

No results posted yet for this study

Summary

Bispecific antibody (BsAb) treatments, teclistamab and elranatamab, are newly available for patients with multiple myeloma who are refractory to all current drugs. The results are very encouraging but complicated adverse events, particularly infectious. This study analyzes survival data in patients treated with BsAb, as well as safety data, in particular the proportions and locations of infectious events. The results are compared to a control cohort. This study is multicentric on all the university hospitals of Paris (AP-HP).

Conditions

Interventions

OTHER

Treated by bispecific antibodies, teclistamab or elranatamab in usual care

Treated by bispecific antibodies, teclistamab or elranatamab in usual care

OTHER

Not treated by bispecific antibodies in usual care

Not treated by bispecific antibodies in usual care

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Jeremie ZERBIT, PharmD · Pharmacy Department, Assistance Publique-Hopitaux de Paris, Université de Paris, Paris, France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06359067 on ClinicalTrials.gov